Victrex (LON:VCT) Announces Quarterly Earnings Results

Victrex (LON:VCT) announced its quarterly earnings data on Monday. The company reported GBX 17.20 earnings per share (EPS) for the quarter, Digital Look Earnings reports. Victrex had a net margin of 9.50% and a return on equity of 6.40%. The business had revenue of £147.10 million for the quarter.

Here are the key takeaways from Victrex’s conference call:

• Victrex’s H1 revenue rose 1% to GBP 147.1 million, helped by a strong Q2 and 6% volume growth, but pricing and mix offset some of the benefit.
• Profitability weakened, with underlying PBT down 18% to GBP 19 million and gross margin falling to 41.7% from 44.1% due to price pressure, mix, currency, and softer medical sales.
• Cash generation remained solid, with free cash flow of GBP 22 million, cash conversion of 109%, and net debt at a manageable 0.65x EBITDA.
• The company recorded a GBP 60.6 million non-cash impairment on its China manufacturing plant after concluding one production step is limiting capacity versus the original 1,500-ton nameplate. Management emphasized this is an operational issue, not a demand issue, and China demand remains strong.
• Management is taking aggressive restructuring actions, including a 10% global headcount reduction, a new decentralized operating model, and portfolio simplification, with a September capital markets day planned to detail the strategy and medium-term profit improvement plan.

Victrex Stock Performance

LON VCT opened at GBX 581 on Monday. The firm’s fifty day moving average price is GBX 612.46 and its two-hundred day moving average price is GBX 644.88. The stock has a market cap of £506.19 million, a PE ratio of 18.27, a PEG ratio of 1.92 and a beta of 0.75. The company has a debt-to-equity ratio of 11.30, a quick ratio of 1.99 and a current ratio of 3.01. Victrex has a fifty-two week low of GBX 515 and a fifty-two week high of GBX 882.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Canaccord Genuity Group restated a “buy” rating and set a GBX 725 price objective on shares of Victrex in a research report on Monday, April 13th. JPMorgan Chase & Co. lowered their target price on Victrex from GBX 725 to GBX 625 and set a “buy” rating for the company in a research note on Wednesday, March 18th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of GBX 750.

About Victrex

Victrex plc, through its subsidiaries, engages in the manufacture and sale of polymer solutions worldwide. The company operates through two segments, Sustainable Solutions and Medical. It develops PEEK and PAEK based polymer solutions, and semi-finished and finished parts. The company also provides specialist solutions for medical device manufacturers; sells thermoplastic polymers; sustainable solutions for energy and industrial, VAR, automotive, aerospace, and electronics markets; and engages in trading activities.